{"title":"Prognostic significance of combined serum immunological HER2 and ERα36 biomarkers in estrogen receptor-positive breast cancer subtypes.","authors":"Yiyang Guo, Shiru Cao, Yanli Deng, Hong Zhang","doi":"10.1080/17520363.2025.2577630","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Breast cancer is the most common cancer among women, with rising incidence and mortality rates, posing clinical treatment challenges.</p><p><strong>Objective: </strong>To analyze the prognostic significance of serum immune HER2 and ERα36 biomarkers in estrogen receptor-positive breast cancer subtypes.</p><p><strong>Methods: </strong>Sixty-one estrogen receptor-positive breast cancer cases from Fourth Hospital of Hebei Medical University (2016-2023) were analyzed. The qPCR was used to detect the expression level of ERα36 mRNA in the sample, and ELISA was used to detect the expression of HER2 in the sample. Associations between biomarker expression, clinicopathological features, and prognosis were evaluated.</p><p><strong>Results: </strong>ERα36 mRNA expression was higher in breast cancer tissues than in adjacent tissues (<i>p</i> < 0.05). High ERα36 expression was associated with menopause (77.78%) and lymph node metastasis (75.00%) (<i>p</i> < 0.05). HER2 positivity correlated with menopause (55.56%) and lymph node metastasis (56.00%) (<i>p</i> < 0.05). No significant differences were found in age, reproductive history, family history, clinical stage, histologic grade, or T stage (<i>p</i> > 0.05). OS rates showed no significant difference, but PFS rates varied significantly (<i>p</i> < 0.05). Patients with high ERα36 expression in HER2-positive cases had the poorest prognosis (<i>p</i> < 0.05).</p><p><strong>Conclusion: </strong>ERα36 and HER2 are valuable prognostic biomarkers, with their co-expression linked to increased lymph node metastasis and poorer survival outcomes.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.1000,"publicationDate":"2025-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2577630","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Breast cancer is the most common cancer among women, with rising incidence and mortality rates, posing clinical treatment challenges.
Objective: To analyze the prognostic significance of serum immune HER2 and ERα36 biomarkers in estrogen receptor-positive breast cancer subtypes.
Methods: Sixty-one estrogen receptor-positive breast cancer cases from Fourth Hospital of Hebei Medical University (2016-2023) were analyzed. The qPCR was used to detect the expression level of ERα36 mRNA in the sample, and ELISA was used to detect the expression of HER2 in the sample. Associations between biomarker expression, clinicopathological features, and prognosis were evaluated.
Results: ERα36 mRNA expression was higher in breast cancer tissues than in adjacent tissues (p < 0.05). High ERα36 expression was associated with menopause (77.78%) and lymph node metastasis (75.00%) (p < 0.05). HER2 positivity correlated with menopause (55.56%) and lymph node metastasis (56.00%) (p < 0.05). No significant differences were found in age, reproductive history, family history, clinical stage, histologic grade, or T stage (p > 0.05). OS rates showed no significant difference, but PFS rates varied significantly (p < 0.05). Patients with high ERα36 expression in HER2-positive cases had the poorest prognosis (p < 0.05).
Conclusion: ERα36 and HER2 are valuable prognostic biomarkers, with their co-expression linked to increased lymph node metastasis and poorer survival outcomes.
期刊介绍：
Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory.
Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice.
As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications.
Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest.
Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
